| Followers | 85 |
| Posts | 6059 |
| Boards Moderated | 0 |
| Alias Born | 09/03/2009 |
Monday, October 12, 2015 1:21:41 PM
If this drops under $4.20 which it probably will then I pocket another 25 g's, how much did you make today holding this over weight pig?
Recent CANF News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/03/2026 09:07:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/01/2026 04:15:14 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:22:12 AM
- Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 • GlobeNewswire Inc. • 03/30/2026 11:20:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/26/2026 02:05:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 01:29:33 PM
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient • GlobeNewswire Inc. • 03/26/2026 01:27:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/17/2026 11:50:36 AM
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance • GlobeNewswire Inc. • 03/17/2026 11:47:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:30:01 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/05/2026 12:31:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:29:04 PM
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds • GlobeNewswire Inc. • 03/04/2026 03:25:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 12:05:05 PM
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 12:01:59 PM
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2026 12:12:14 PM
- Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy • GlobeNewswire Inc. • 02/09/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/05/2026 12:03:25 PM
- Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson • GlobeNewswire Inc. • 02/05/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/27/2026 09:15:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/20/2026 12:01:37 PM
